Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Article in the FT last week or week before but a 63p target in the short term...
It will be interesting to see what they have planned here, there are no real genetic offerings in this space and perhaps they are focusing on fertility based genetic testing?
Once C E-IVD is given and sales start to come in from a number of different territories this will rise quickly. LTHs know there is a £150m+ market cap to be had here eventually ONCE sales roll in over the coming years. An exciting business to be in. Short term expect rises and falls, medium and long term this is moving up from here. End of year really depends on news flow...
https://www.nature.com/articles/nrd.2017.243
for anyone interested on the vaccine...
A lot more to come as more data vaccine becomes available, particularly around side effects such as immune enhancement; auto-reactive antibodies and autoimmune problems are not insignificant concerns with these types of vaccines and previous attempts to create a coronavirus vaccine have failed in large part because of these....
If you extract RNA from a sample you get a certain number of copies per ul of extracted sample. This is determined by how much virus is in the sample. 5ul will have 5x fewer copies than 25ul. A larger amount of sample transferred to the test will always give a better performance down at the LOD.
Say a test has an LOD of 10 copies and my extraction has 1 copy per ul. The 5ul reaction would have 5 copies, below the LOD and will not give a positive result. A 25ul reaction will have 25 copies, 2.5x the test LOD and will give a positive result. It’s about having copies in your sample.
Reducing the test volume reduces your test performance at the LOD of the test...
But as I said, sometimes that’s fine if you want to pass low copy numbers as negative results...
My use of the word sensitivity was ambiguous. If you have 20ul of a sample going into a 96-well test which has a 4x higher volume than 384-well test which is only 5ul, then you are putting in 25% of the sample you would have when using a 384 well plate compared to a 96 well plate. This has a 75% impact on the limit of detection per ml of sample. It's the LOD that drops, but there may be political reasons why you'd want to do this, it will mean low level infections aren't picked up and reported.
We are not involved. DB said as much in his presentation because the Lighthouse labs are focusing of 384 well plates as a means to get their numbers up - forget abut the 75% drop in sensitivity that results! Bad move, no infectious disease diagnostics are done in that low volume because of sensitivity issues but hey ho.
This RNS demonstrates how well the platform works at POC, it shouldn’t be underestimated. There are no other rapid true POC PCR devices out there. The closest competition is Cepheid, but their device isn’t portable or POC, it needs a lab to support it, GDR doesn’t. Hopefully the market will wake up to this. The world needs POC diagnostics.... both HCV and AIHL are proving that GDR can lead the way!
Agree Allah, I'm not convinced the UK is where they should head. Many countries that don't have infrastructure will not have access to the new mRNA vaccines and will need a room temperature stable test to continue testing their populations. This is where GDR are focused and I suspect will roll out once FDA or Indian approvals land.
I agree flying, now that it exists they have to use it once it has FDA. I wasn't sure if they have yet applied for FDA though, I need to re-run the presentation. In any event, I think Dave underestimates the world market if this becomes a standard of care for triaging antibiotic use in infants